{"id":"bayer-acarbose","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"15-25","effect":"Diarrhea"},{"rate":null,"effect":"Hypoglycemia (when combined with other agents)"}]},"_chembl":{"chemblId":"CHEMBL4299399","moleculeType":"Small molecule","molecularWeight":"645.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acarbose is an alpha-glucosidase inhibitor that delays the breakdown of disaccharides and complex carbohydrates in the small intestine. By slowing carbohydrate absorption, it reduces the rate at which glucose enters the bloodstream after meals, thereby lowering postprandial glucose excursions in patients with diabetes. This mechanism helps improve glycemic control without stimulating insulin secretion.","oneSentence":"Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:38.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Postprandial hyperglycemia in type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01914133","phase":"PHASE2","title":"Acarbose and Older Adults With Postprandial Hypotension","status":"COMPLETED","sponsor":"Kenneth Madden","startDate":"2014-01","conditions":"Other Specified Hypotension, Syncope","enrollment":42},{"nctId":"NCT02438397","phase":"PHASE4","title":"the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin","status":"UNKNOWN","sponsor":"Shanghai 6th People's Hospital","startDate":"2014-12","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT01316861","phase":"PHASE3","title":"Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"EMS","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":79},{"nctId":"NCT01624116","phase":"NA","title":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2011-08","conditions":"Diabetes, Type 2","enrollment":161}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":73,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bayer Acarbose","genericName":"Bayer Acarbose","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes. Used for Type 2 diabetes mellitus, Postprandial hyperglycemia in type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}